Asset Details
Do you wish to reserve the book?
Predicting Late-stage Breast Cancer Diagnosis and Receipt of Adjuvant Therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Predicting Late-stage Breast Cancer Diagnosis and Receipt of Adjuvant Therapy
Do you wish to request the book?
Predicting Late-stage Breast Cancer Diagnosis and Receipt of Adjuvant Therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Predicting Late-stage Breast Cancer Diagnosis and Receipt of Adjuvant Therapy
2015
Overview
PURPOSE:The 2-step floating catchment area (2SFCA) method of measuring access to care has never been used to study cancer disparities in Appalachia. First, we evaluated the 2SFCA method in relation to traditional methods. We then examined the impact of access to mammography centers and primary care on late-stage breast cancer diagnosis and receipt of adjuvant hormonal therapy.
METHODS:Cancer registries from Pennsylvania, Ohio, Kentucky, and North Carolina were linked with Medicare data to identify the stage of breast cancer diagnosis for Appalachia women diagnosed between 2006 and 2008. Women eligible for adjuvant therapy had stage I, II, or III diagnosis; mastectomy or breast-conserving surgery; and hormone receptor–positive breast cancers. Geographically weighted regression was used to explore nonstationarity in the demographic and spatial access predictor variables.
RESULTS:Over 21% of 15,299 women diagnosed with breast cancer had late-stage (stages III–IV) diagnosis. Predictors included age at diagnosis [odds ratio (OR)=0.86; P<0.001], insurance status (OR=1.32; P<0.001), county primary care to population ratio (OR=0.95; P<0.001), and primary-care 2SFCA score (OR=0.96; P=0.006). Only 46.9% of eligible women received adjuvant hormonal therapy, and predictors included comorbidity status (OR=1.18; P=0.047), county economic status (OR=1.32; P=0.006), and mammography center 2SFCA scores (OR=1.12; P=0.021).
CONCLUSIONS:Methodologically, the 2SFCA method offered the greatest predictive validity of the access measures examined. Substantively, rates of late-stage breast cancer diagnosis and adjuvant hormonal therapy are substandard in Appalachia.
Publisher
Lippincott Williams & Wilkins,Copyright Wolters Kluwer Health, Inc. All rights reserved,Lippincott Williams & Wilkins Ovid Technologies
Subject
/ Breast Neoplasms - diagnosis
/ Breast Neoplasms - drug therapy
/ Breast Neoplasms - epidemiology
/ Chemotherapy, Adjuvant - statistics & numerical data
/ Early Detection of Cancer - statistics & numerical data
/ Female
/ Health Services Accessibility - statistics & numerical data
/ Healthcare Disparities - statistics & numerical data
/ Humans
/ Mammography - statistics & numerical data
